美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Global X China Biotech Innovation ETF

6.64

0.0000

成交量：- -

成交额：- -

市值：139.44万

市盈率：- -

高：6.64

开：6.64

低：6.64

收：6.64

52周最高：6.64

52周最低：6.64

股本：21.00万

流通股本：21.00万

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

告别终身服药？乙肝患者有望迎来“功能性治愈”时代

探索“功能性治愈”新路径，展望“无乙肝的未来”

抗体浪潮风起，这家Biotech紧抓机遇

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CHB"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CHB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHB\",,,,,undefined,":{"symbol":"CHB","market":"US","secType":"STK","nameCN":"Global X China Biotech Innovation ETF","latestPrice":6.64,"timestamp":1739998800000,"preClose":6.64,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":210000,"shares":210000,"eps":0,"marketStatus":"盘后交易","change":0,"latestTime":"02-10 18:15:34 EST","open":6.64,"high":6.64,"low":6.64,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770771600000},"marketStatusCode":4,"adr":0,"listingDate":1601006400000,"exchange":"NASDAQ","adjPreClose":6.64,"sharesOutstanding":210000,"nav":6.72,"aum":1412042.9,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHB\",,,,,undefined,":{"symbol":"CHB","floatShares":210000,"roa":"--","roe":"--","lyrEps":0,"shares":210000,"dividePrice":0,"high":6.64,"amplitude":0,"preClose":6.64,"low":6.64,"week52Low":6.64,"pbRate":"--","week52High":6.64,"institutionHeld":0,"latestPrice":6.64,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":6.64,"prevYearClose":6.64,"prevWeekClose":6.64,"prevMonthClose":6.64,"prevQuarterClose":6.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-20","symbol":"CHB","reason":null,"defaultRemindTime":1708439400000,"announcedDate":"2024-02-16","type":"delisting","dateTimestamp":1708405200000},{"date":"2023-12-28","symbol":"CHB","amount":0.001878,"announcedDate":"2023-12-27","type":"dividend","market":"US","newRecordDate":"2023-12-29","defaultRemindTime":1703773800000,"name":"Global X China Biotech Innovation ETF","recordDate":"2024-01-08","payableDate":"2023-12-29","currency":"USD","dateTimestamp":1703739600000,"payDate":"2024-01-08"},{"date":"2023-06-29","symbol":"CHB","amount":0.037027,"announcedDate":"2023-06-28","type":"dividend","market":"US","newRecordDate":"2023-06-30","defaultRemindTime":1688045400000,"name":"Global X China Biotech Innovation ETF","recordDate":"2023-07-10","payableDate":"2023-06-30","currency":"USD","dateTimestamp":1688011200000,"payDate":"2023-07-10"},{"market":"US","date":"2022-06-29","symbol":"CHB","amount":0.019889,"defaultRemindTime":1656509400000,"name":"Global X China Biotech Innovation ETF","recordDate":"2022-07-08","payableDate":"2022-06-30","currency":"USD","type":"dividend","dateTimestamp":1656475200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHB\",market:\"US\",,,undefined,":[{"executeDate":"2022-06-29","recordDate":"2022-06-30","paymentDate":"2022-07-08","value":0.019889,"currency":"USD"},{"executeDate":"2023-06-29","recordDate":"2023-06-30","paymentDate":"2023-07-10","value":0.037027,"currency":"USD"},{"executeDate":"2023-12-28","recordDate":"2023-12-29","paymentDate":"2024-01-08","value":0.001878,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHB\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2601354162","title":"告别终身服药？乙肝患者有望迎来“功能性治愈”时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2601354162","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601354162?lang=zh_cn&edition=fundamental","pubTime":"2026-01-08 16:44","pubTimestamp":1767861897,"startTime":"0","endTime":"0","summary":"当地时间1月7日，英国制药公司葛兰素史克（GSK）宣布在研慢性乙肝疗法Bepirovirsen在两项关键三期临床试验中均达到主要终点。如果该药物获批，将意味着全球首个仅需6个月有限疗程治疗，便可直接实现乙肝功能性治愈的抗病毒疗法诞生。Bepirovirsen是一种新型反义寡核苷酸（ASO）乙肝抗病毒疗法，可直接抑制病毒复制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601083612803644.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601083612803644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","ASO","BK4561","BK4532","GSK","NA","BK4141","LU1829250122.USD","BK4585","CHB","BK4007","BK4200","BK4588"],"gpt_icon":0},{"id":"2582608828","title":"探索“功能性治愈”新路径，展望“无乙肝的未来”","url":"https://stock-news.laohu8.com/highlight/detail?id=2582608828","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582608828?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 15:45","pubTimestamp":1762760739,"startTime":"0","endTime":"0","summary":"在第八届中国国际进口博览会上，葛兰素史克（GSK）举办了以“为了没有乙肝的未来”为主题的医学专场活动，聚焦慢性乙型肝炎（CHB）防治与“功能性治愈”的前沿突破，探讨乙肝防治的最新科研进展与未来诊疗格局的变革。从控制到治愈：乙肝防治进入“存量管理”新阶段我国乙肝防治历经三十余年努力，疫苗接种构筑起坚实防线，使新发感染率显著下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://biz.eastmoney.com/a/202511103559749093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","BK4007","BK4585","BK4588","ASO","LU1829250122.USD","BK4561","CHB","BK4532","BK4200","GSK"],"gpt_icon":0},{"id":"2560929367","title":"抗体浪潮风起，这家Biotech紧抓机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2560929367","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560929367?lang=zh_cn&edition=fundamental","pubTime":"2025-08-17 06:24","pubTimestamp":1755383098,"startTime":"0","endTime":"0","summary":"Vir Biotechnology不得不忙起来。7月，这家Biotech启动了第四款抗肿瘤候选药物的临床研究，尽管作为核心管线慢性丁型肝炎疗法tobevibart，相关III期试验也处于患者招募阶段。不过，相较Biotech间的联合，Vir一以贯之选择“大树好乘凉”。2025年以来，Vir的股价跌幅超过40%。VIR-5500和VIR-5818均处于积极剂量递增阶段，Vir每三周对VIR-5818进行一次剂量研究。7月31日，Vir又为ECLIPSE 2招募到首位患者。值得注意的是，Vir还把tobevibart与elebsiran的大中华区权益授予腾盛博药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817062744a48cdf2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817062744a48cdf2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4139","BK4535","CHD","BK4588","CHB","LU1430594728.SGD","BK4504","BK4551","BK4568","BK4585","BNTX","LU1585245621.USD","BK4018"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CHB\",params:#limit:6,delay:false,,,undefined,":[]}}